Gut Microbiota and Their Metabolites in the Progression of Non-alcoholic Fatty Liver Disease

Overview

Journal Hepatoma Res

Date 2021 Jan 25

PMID 33490737

Citations 20

Authors

Jin Zhou

Madhulika Tripathi

Rohit A Sinha

Brijesh Kumar Singh

Paul M Yen

Affiliations

Soon will be listed here.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disorder worldwide. It comprises a spectrum of conditions that range from steatosis to non-alcoholic steatohepatitis, with progression to cirrhosis and hepatocellular carcinoma. Currently, there is no FDA-approved pharmacological treatment for NAFLD. The pathogenesis of NAFLD involves genetic and environmental/host factors, including those that cause changes in intestinal microbiota and their metabolites. In this review, we discuss recent findings on the relationship(s) of microbiota signature with severity of NAFLD and the role(s) microbial metabolites in NAFLD progression. We discuss how metabolites may affect NAFLD progression and their potential to serve as biomarkers for NAFLD diagnosis or therapeutic targets for disease management.

Citing Articles

Unraveling the Role of the Human Gut Microbiome in Health and Diseases.

Khalil M, Di Ciaula A, Mahdi L, Jaber N, Di Palo D, Graziani A Microorganisms. 2024; 12(11).

PMID: 39597722 PMC: 11596745. DOI: 10.3390/microorganisms12112333.

Emerging Therapies for Non-Alcoholic Steatohepatitis (NASH): A Comprehensive Review of Pharmacological and Non-Pharmacological Approaches.

Kakde S, Mushtaq M, Liaqat M, Ali H, Mushtaq M, Sarwer M Cureus. 2024; 16(9):e69129.

PMID: 39398771 PMC: 11467241. DOI: 10.7759/cureus.69129.

Impact of gut microbiota on metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma: pathways, diagnostic opportunities and therapeutic advances.

Kumar A, Nair B, Kamath A, Nath L, Calina D, Sharifi-Rad J Eur J Med Res. 2024; 29(1):485.

PMID: 39367507 PMC: 11453073. DOI: 10.1186/s40001-024-02072-3.

Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets.

Gruzdev S, Podoprigora I, Gizinger O Arch Microbiol. 2024; 206(2):62.

PMID: 38216746 DOI: 10.1007/s00203-023-03752-0.

New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut-Liver-Heart Crosstalk.

Yang K, Song M Nutrients. 2023; 15(18).

PMID: 37764755 PMC: 10534946. DOI: 10.3390/nu15183970.

References

Powell E, Cooksley W, Hanson R, Searle J, Halliday J, Powell L . The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990; 11(1):74-80. DOI: 10.1002/hep.1840110114. View

Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F . The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2015; 63(3):764-75. PMC: 4975935. DOI: 10.1002/hep.28356. View

Pedrosa M, Seyedkazemi S, Francque S, Sanyal A, Rinella M, Charlton M . A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemp Clin Trials. 2019; 88:105889. DOI: 10.1016/j.cct.2019.105889. View

Hu H, Lin A, Kong M, Yao X, Yin M, Xia H . Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. J Gastroenterol. 2019; 55(2):142-158. PMC: 6981320. DOI: 10.1007/s00535-019-01649-8. View

Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A . Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017; 25(5):1054-1062.e5. PMC: 5502730. DOI: 10.1016/j.cmet.2017.04.001. View

Jansen P . Endogenous bile acids as carcinogens. J Hepatol. 2007; 47(3):434-5. DOI: 10.1016/j.jhep.2007.06.001. View

Engstler A, Aumiller T, Degen C, Durr M, Weiss E, Maier I . Insulin resistance alters hepatic ethanol metabolism: studies in mice and children with non-alcoholic fatty liver disease. Gut. 2015; 65(9):1564-71. DOI: 10.1136/gutjnl-2014-308379. View

Bures J, Cyrany J, Kohoutova D, Forstl M, Rejchrt S, Kvetina J . Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010; 16(24):2978-90. PMC: 2890937. DOI: 10.3748/wjg.v16.i24.2978. View

Michail S, Lin M, Frey M, Fanter R, Paliy O, Hilbush B . Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol. 2015; 91(2):1-9. PMC: 4358749. DOI: 10.1093/femsec/fiu002. View

10.

Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M . Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 2018; 360(6391). PMC: 6407885. DOI: 10.1126/science.aan5931. View

11.

Rafiei R, Bemanian M, Rafiei F, Bahrami M, Fooladi L, Ebrahimi G . Liver disease symptoms in non-alcoholic fatty liver disease and small intestinal bacterial overgrowth. Rom J Intern Med. 2017; 56(2):85-89. DOI: 10.1515/rjim-2017-0042. View

12.

Ferslew B, Xie G, Johnston C, Su M, Stewart P, Jia W . Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis. Dig Dis Sci. 2015; 60(11):3318-28. PMC: 4864493. DOI: 10.1007/s10620-015-3776-8. View

13.

Porras D, Nistal E, Martinez-Florez S, Gonzalez-Gallego J, Garcia-Mediavilla M, Sanchez-Campos S . Intestinal Microbiota Modulation in Obesity-Related Non-alcoholic Fatty Liver Disease. Front Physiol. 2019; 9:1813. PMC: 6305464. DOI: 10.3389/fphys.2018.01813. View

14.

Mehedint M, Zeisel S . Choline's role in maintaining liver function: new evidence for epigenetic mechanisms. Curr Opin Clin Nutr Metab Care. 2013; 16(3):339-45. PMC: 3729018. DOI: 10.1097/MCO.0b013e3283600d46. View

15.

Chen Y, Wu W, Wu M . Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review. Int J Mol Sci. 2020; 21(17). PMC: 7504062. DOI: 10.3390/ijms21175999. View

16.

Appleby R, Moghul I, Khan S, Yee M, Manousou P, Neal T . Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study. PLoS One. 2019; 14(1):e0211348. PMC: 6347262. DOI: 10.1371/journal.pone.0211348. View

17.

Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M . A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003; 278(11):9435-40. DOI: 10.1074/jbc.M209706200. View

18.

Gangarapu V, Ince A, Baysal B, Kayar Y, Kilic U, Gok O . Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2015; 27(7):840-5. DOI: 10.1097/MEG.0000000000000348. View

19.

Schaap F, Trauner M, Jansen P . Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol. 2013; 11(1):55-67. DOI: 10.1038/nrgastro.2013.151. View

20.

Pencek R, Marmon T, Roth J, Liberman A, Hooshmand-Rad R, Young M . Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers. Diabetes Obes Metab. 2016; 18(9):936-40. DOI: 10.1111/dom.12681. View